Menarini News / 3

By marking #BPDCNday, Menarini Group is giving a rare and aggressive blood cancer nowhere to hide

Together, we make a difference Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy that often manifests with skin lesions. Although BPDCN is mostly diagnosed in elderly patients, it may occur at any age,1,2 with men three times more likely to be affected than women. There are roughly 700 cases in the United []

trending_flat Read more

Menarini launches “Infection in Focus” portal to fight antimicrobial resistance

Ever since penicillin was discovered in 1928, antibiotics, medicines used to prevent and treat bacterial infections, have made an enormous contribution to global health and diseases that were once deemed to be fatal have been successfully treated for decades. The development of antibiotics is recognised as one of the greatest advances in therapeutic medicine. Antibiotics []

trending_flat Read more

The acquisition of US company Stemline Therapeutics: a brave move that rewards Menarini at M&A Award 2021

2020 has been an unprecedentedly arduous year around the world. Many industrial sectors – including pharmaceuticals and healthcare – have been affected by the pandemic. In such a delicate context, undertaking a $677 million operation by purchasing 100% of the shares of a major US biopharmaceutical company was a bold move, that allowed Menarini Group []

trending_flat Read more